Increased Interleukin-17 In The Cerebrospinal Fluid In Sporadic Creutzfeldt-Jakob Disease (P5.234)

OBJECTIVE: To detect CNS inflammatory responses which can be associated with the pathogenesis of sporadic Creutzfeldt-Jakob disease (sCJD). BACKGROUND: Inflammatory responses in the cerebrospinal fluid (CSF) of patients with sCJD remain elusive. DESIGN/METHODS: We conducted a case-control study. Fourteen patients with sCJD, 14 with non-inflammatory neurological disorders and 14 with autoimmune encephalitis were enrolled. We used the suspension array system to measure the concentrations of 27 cytokines in CSF. The cytokine titers of the 3 groups were compared, and the correlation between the relevant cytokine titers and clinical parameters were investigated in the patients with sCJD. RESULTS: The 2 cytokines interleukin (IL)-1 receptor antagonist and IL-17 were significantly elevated in the patients with sCJD compared with those in the patients with non-inflammatory neurological disorders: IL-17 in sCJD was approximately 10 times higher compared with that in the non-inflammatory neurological disorders (mean, 35.46 vs. 3.45 pg/ml; p < 0.001) but comparable to that in encephalitis (mean, 32.16 pg/ml). In contrast, classical pro-inflammatory cytokines such as IL-12(p70) and tumor necrosis factor-α were increased only in encephalitis. Although not significant, IL-17 titers tended to be higher in the patients with shorter disease duration before CSF sampling (r = −0.452; p = 0.104) and in those with lower CSF total protein concentrations (r = −0.473; p = 0.086). CONCLUSIONS: IL-17 is significantly increased in CSF in sCJD, which can be an early event in the pathogenesis of sCJD. Study Supported by: JSPS KAKENHI Grant Number 25860715. Disclosure: Dr. Fujita has nothing to disclose. Dr. Matsui has nothing to disclose. Dr. Takahashi has nothing to disclose. Dr. Iwasaki has nothing to disclose. Dr. Yoshida has nothing to disclose. Dr. Yuasa has nothing to disclose. Dr. Izumi has nothing to disclose. Dr. Kaji has received personal compensation for activities with GlaxoSmithKline, Inc. as a consultant. Dr. Kaji has received research support from GlaxoSmithKline, Inc.